抗がんモノクローナル抗体（mAb）の世界市場規模調査＆予測：タイプ別、用途別、エンドユーザー別、地域別分析、2023-2030年

抗がんモノクローナル抗体（mAb）は、がん細胞や腫瘍微小環境に発現する抗原を特異的に標的として結合するように作られます。

これらの抗体は、がん細胞に対する身体の免疫学的反応に影響を与えたり、腫瘍の発生を抑制したり、がんと闘う免疫系の能力を高めたり、細胞毒性化学物質を腫瘍細胞に直接輸送したりすることができます。抗がんmAbの市場は、世界のがんの罹患率と有病率の上昇、がん生物学に関する知識の拡大と新規治療標的の発見、バイオテクノロジーと抗体工学的手法の改善といった要因によって牽引されています。

米国臨床腫瘍学会は、2022年末までに米国で190万人ががんと診断され、60万9360人ががんに関連した死亡に至ると予測しています。さらに、同じ情報源からの推計によると、2020年には世界で176,000人が多発性骨髄腫と診断されています。2022年には34,000人以上が多発性骨髄腫の診断を受け、米国では12,000人以上が亡くなると予想されています。ここ数年、さまざまながんを治療するために、10以上のモノクローナル抗体がFDAの承認を受けています。さらに、GamaMabs Pharma SAは2021年5月、500万米ドルのゲノミクスに基づく医薬品開発企業であるExelixis Inc.に買収されました。Exelixis Inc.は、GamaMabsのAMHR2抗体技術を取得することで、GamaMabsの現在の治療製品群および関連する製造用細胞株を拡大する意向です。GamaMabs Pharma SAはフランスに設立されたバイオテクノロジー企業で、固形がん治療のための新規モノクローナル抗体の創製に専念しています。しかし、高額な治療費と副作用・安全性の懸念が、2023-2030年の予測期間を通じて市場の成長を阻害しています。

抗がんモノクローナル抗体の世界市場調査において考慮した主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカです。北米は、提携や共同研究といった戦略の台頭により、主要地域となっています。しかし、アジア太平洋地域は、特に先進国や新興国の事業体間の国際的および国内的な協力関係の増加により、最も急成長している地域であると予想され、市場の推進が期待されています。

本調査の目的は、近年のさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的・量的側面を盛り込むよう設計されています。

また、市場の将来的な成長を定義すると予想される促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

• 市場スナップショット
• 世界市場・セグメント別市場推計・予測、2020-2030年
  • 抗がんモノクローナル抗体市場：地域別、2020-2030年
  • 抗がんモノクローナル抗体市場：タイプ別、2020-2030年
  • 抗がんモノクローナル抗体市場：用途別、2020-2030年
  • 抗がんモノクローナル抗体市場：エンドユーザー別、2020-2030年
• 主要動向
• 調査手法
• 調査前提条件

第2章 抗がんモノクローナル抗体の世界市場定義とスコープ

• 調査目的
• 市場の定義と範囲
  • 産業の進化
  • 調査範囲
• 調査対象年
• 通貨換算レート

第3章 抗がんモノクローナル抗体の世界市場力学

• 抗がんモノクローナル抗体市場のインパクト分析（2020-2030年）
  • 市場促進要因
    • がんの有病率の増加
    • 製薬産業の成長
  • 市場の課題
    • 治療費の高騰
    • 副作用と安全性への懸念
  • 市場機会
    • 新規ターゲットの開発
    • 抗がんmAbと他の免疫療法の統合

第4章 世界の抗がんモノクローナル抗体市場の産業分析

• ポーターの5フォースモデル
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係
• ポーターの5フォース影響分析
• PEST分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 環境
  • 法律
• 主な投資機会
• 主要成功戦略
• COVID-19影響分析
• 破壊的動向
• 業界専門家の視点
• アナリストの結論・提言

第5章 抗がんモノクローナル抗体の世界市場：タイプ別

• 市場スナップショット
• 抗がんモノクローナル抗体の世界市場：タイプ別、実績 - ポテンシャル分析
• 抗がんモノクローナル抗体の世界市場：タイプ別推定・予測、2020～2030年
• 抗がんモノクローナル抗体市場、サブセグメント別分析
  • マウス抗体
  • キメラ抗体
  • ヒト化抗体
  • その他のタイプ

第6章 抗がんモノクローナル抗体の世界市場：用途別

• 市場スナップショット
• 抗がんモノクローナル抗体の世界市場：用途別、実績 - ポテンシャル分析
• 抗がんモノクローナル抗体の世界市場：用途別推定・予測、2020～2030年
• 抗がんモノクローナル抗体市場、サブセグメント別分析
  • 血液がん
  • 乳がん
  • 肺がん
  • メラノーマ
  • 大腸がん
  • 肝臓がん
  • その他の用途

第7章 抗がんモノクローナル抗体の世界市場：エンドユーザー別

• 市場スナップショット
• 抗がんモノクローナル抗体の世界市場：エンドユーザー別、実績-ポテンシャル分析
• エンドユーザー別抗がんモノクローナル抗体の世界市場推計・予測、2020～2030年
• 抗がんモノクローナル抗体市場、サブセグメント別分析
  • 病院
  • 研究機関
  • その他のエンドユーザー

第8章 抗がんモノクローナル抗体の世界市場：地域別分析

• 主要国
• 主な新興国
• 抗がんモノクローナル抗体市場、地域別市場スナップショット
• 北米
  • 米国
    • タイプ別推定・予測、2020-2030年
    • 用途の推定・予測、2020-2030年
    • エンドユーザーの推定・予測、2020～2030年
  • カナダ
• 欧州の抗がんモノクローナル抗体市場スナップショット
  • 英国
  • ドイツ
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• アジア太平洋の抗がんモノクローナル抗体市場スナップショット
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカの抗がんモノクローナル抗体市場スナップショット
  • ブラジル
  • メキシコ
• 中東・アフリカ
  • サウジアラビア
  • 南アフリカ
  • その他中東・アフリカ

第9章 競合情報

• 主要企業のSWOT分析
• 主要市場戦略
• 企業プロファイル
  • Amgen Inc.
    • 主要情報
    • 概要
    • 財務（データの入手が可能な場合）
    • 製品概要
    • 最近の動向
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genmab AS
  • Novartis AG
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson Corp.
  • AbbVie, Inc

第10章 調査プロセス

• 調査プロセス
  • データマイニング
  • 分析
  • 市場推定
  • 検証
  • 出版
• 調査属性
• 調査前提条件

LIST OF TABLES

• TABLE 1. Global Anticancer monoclonal antibodies Market, report scope
• TABLE 2. Global Anticancer monoclonal antibodies Market estimates & forecasts by Region 2020-2030 (USD Billion)
• TABLE 3. Global Anticancer monoclonal antibodies Market estimates & forecasts by Type 2020-2030 (USD Billion)
• TABLE 4. Global Anticancer monoclonal antibodies Market estimates & forecasts by Application 2020-2030 (USD Billion)
• TABLE 5. Global Anticancer monoclonal antibodies Market estimates & forecasts by End User 2020-2030 (USD Billion)
• TABLE 6. Global Anticancer monoclonal antibodies Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 7. Global Anticancer monoclonal antibodies Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 8. Global Anticancer monoclonal antibodies Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 9. Global Anticancer monoclonal antibodies Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 10. Global Anticancer monoclonal antibodies Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 11. Global Anticancer monoclonal antibodies Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 12. Global Anticancer monoclonal antibodies Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 13. Global Anticancer monoclonal antibodies Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 14. Global Anticancer monoclonal antibodies Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 15. Global Anticancer monoclonal antibodies Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 16. U.S. Anticancer monoclonal antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 17. U.S. Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 18. U.S. Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 19. Canada Anticancer monoclonal antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 20. Canada Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 21. Canada Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 22. UK Anticancer monoclonal antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 23. UK Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 24. UK Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 25. Germany Anticancer monoclonal antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 26. Germany Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 27. Germany Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 28. France Anticancer monoclonal antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 29. France Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 30. France Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 31. Italy Anticancer monoclonal antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 32. Italy Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 33. Italy Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 34. Spain Anticancer monoclonal antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 35. Spain Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 36. Spain Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 37. RoE Anticancer monoclonal antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 38. RoE Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 39. RoE Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 40. China Anticancer monoclonal antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 41. China Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 42. China Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 43. India Anticancer monoclonal antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 44. India Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 45. India Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 46. Japan Anticancer monoclonal antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 47. Japan Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 48. Japan Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 49. South Korea Anticancer monoclonal antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 50. South Korea Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 51. South Korea Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 52. Australia Anticancer monoclonal antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 53. Australia Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 54. Australia Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 55. RoAPAC Anticancer monoclonal antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 56. RoAPAC Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 57. RoAPAC Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 58. Brazil Anticancer monoclonal antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 59. Brazil Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 60. Brazil Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 61. Mexico Anticancer monoclonal antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 62. Mexico Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 63. Mexico Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 64. RoLA Anticancer monoclonal antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 65. RoLA Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 66. RoLA Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 67. Saudi Arabia Anticancer monoclonal antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 68. South Africa Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 69. RoMEA Anticancer monoclonal antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 70. List of secondary sources, used in the study of global Anticancer monoclonal antibodies Market
• TABLE 71. List of primary sources, used in the study of global Anticancer monoclonal antibodies Market
• TABLE 72. Years considered for the study
• TABLE 73. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

• FIG 1. Global Anticancer monoclonal antibodies Market, research methodology
• FIG 2. Global Anticancer monoclonal antibodies Market, Market estimation techniques
• FIG 3. Global Market size estimates & forecast methods
• FIG 4. Global Anticancer monoclonal antibodies Market, key trends 2022
• FIG 5. Global Anticancer monoclonal antibodies Market, growth prospects 2023-2030
• FIG 6. Global Anticancer monoclonal antibodies Market, porters 5 force model
• FIG 7. Global Anticancer monoclonal antibodies Market, pest analysis
• FIG 8. Global Anticancer monoclonal antibodies Market, value chain analysis
• FIG 9. Global Anticancer monoclonal antibodies Market by segment, 2020 & 2030 (USD Billion)
• FIG 10. Global Anticancer monoclonal antibodies Market by segment, 2020 & 2030 (USD Billion)
• FIG 11. Global Anticancer monoclonal antibodies Market by segment, 2020 & 2030 (USD Billion)
• FIG 12. Global Anticancer monoclonal antibodies Market by segment, 2020 & 2030 (USD Billion)
• FIG 13. Global Anticancer monoclonal antibodies Market by segment, 2020 & 2030 (USD Billion)
• FIG 14. Global Anticancer monoclonal antibodies Market, regional snapshot 2020 & 2030
• FIG 15. North America Anticancer monoclonal antibodies Market 2020 & 2030 (USD Billion)
• FIG 16. Europe Anticancer monoclonal antibodies Market 2020 & 2030 (USD Billion)
• FIG 17. Asia pacific Anticancer monoclonal antibodies Market 2020 & 2030 (USD Billion)
• FIG 18. Latin America Anticancer monoclonal antibodies Market 2020 & 2030 (USD Billion)
• FIG 19. Middle East & Africa Anticancer monoclonal antibodies Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

Global Anticancer monoclonal antibodies Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Anti-cancer monoclonal antibodies are made to specifically target and bind to antigens expressed on cancer cells or in the tumour microenvironment. These antibodies can influence the body's immunological response to cancer cells, suppress tumour development, boost the immune system's ability to fight cancer, and transport cytotoxic chemicals directly to tumour cells, among other processes. The market for anti-cancer MAbs is being driven by factors such as the rising incidence and prevalence of cancer in the globe, the expanding knowledge of cancer biology and the discovery of novel therapeutic targets, and improvements in biotechnology and antibody engineering methods.

The American Society of Clinical Oncology predicts that by the end of 2022, there have been 1.9 million cancer diagnoses and 609,360 cancer-related deaths in the United States. Additionally, estimations from the same source suggested that 176,000 people had multiple myeloma diagnoses globally in 2020. More than 34,000 people given a multiple myeloma diagnosis in 2022, and more than 12,000 people expected to pass away in the United States. More than a dozen monoclonal antibodies have received FDA approval in the last few years to treat different cancers. Furthermore, GamaMabs Pharma SA was purchased by Exelixis Inc., a USD 5 million genomics-based drug development company, in May 2021. Exelixis Inc. intends to expand its current therapeutic product range of GamaMabs and related manufacturing cell lines by acquiring GamaMabs' AMHR2 antibody technology. The biotechnology company GamaMabs Pharma SA is established in France and is dedicated to creating novel monoclonal antibodies for the treatment of solid tumours. However, the high cost of treatment and side Effects and Safety Concerns stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Anticancer monoclonal antibodies Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is the leading region owing to rising strategies such as partnership and collaboration. However, Asia Pacific is expected to be the fastest growing region due to the increasing number of international and national collaborations among entities, especially those in developed and developing countries, which is expected to propel the market.

Major market players included in this report are:

• Amgen Inc.
• Bristol Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Genmab AS
• Novartis AG
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Johnson & Johnson Corp.
• AbbVie, Inc.

Recent Developments in the Market:

• In May 2022, PHESGO was introduced by Roche Holding AG, a pharmaceutical business located in Switzerland. Pertuzumab, trastuzumab, and hyaluronidase-zzxf, or PHESGO, is a novel monoclonal antibody (mAb) combination therapy for early breast cancer that is HER2-positive. The two monoclonal antibodies (mAbs) pertuzumab and trastuzumab, along with the enzyme hyaluronidase, are administered subcutaneously (under the skin).
• In 2021, GamaMabs Pharma SA was purchased by Exelixis Inc., a genomics-based medicine discovery business with headquarters in the US, for USD 5 million. Exelixis Inc. intends to expand its current therapeutic product range of GamaMabs and related manufacturing cell lines by acquiring GamaMabs' AMHR2 antibody technology.

Global Anticancer monoclonal antibodies Market Report Scope:

• Historical Data: 2020 - 2021
• Base Year for Estimation: 2022
• Forecast period: 2023-2030
• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: Type, Application, End User, Region
• Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which expected to define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:

• Murine Antibodies
• Chimeric Antibodies
• Humanized Antibodies
• Other Types

By Application:

• Blood Cancer
• Breast Cancer
• Lung Cancer
• Melanoma
• Colorectal Cancer
• Liver Cancer
• Other Applications

By End User:

• Hospitals
• Research Institutes
• Other End Users

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Anticancer monoclonal antibodies Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2. Anticancer monoclonal antibodies Market, by Type, 2020-2030 (USD Billion)
  • 1.2.3. Anticancer monoclonal antibodies Market, by Application, 2020-2030 (USD Billion)
  • 1.2.4. Anticancer monoclonal antibodies Market, by End User, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Anticancer monoclonal antibodies Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Anticancer monoclonal antibodies Market Dynamics

• 3.1. Anticancer monoclonal antibodies Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Increase in prevalence of cancer
    • 3.1.1.2. Increase in growth of Pharmaceutical Industry
  • 3.1.2. Market Challenges
    • 3.1.2.1. High cost of treatment
    • 3.1.2.2. Side Effects and Safety Concerns
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Development of Novel Targets
    • 3.1.3.2. Integration of anti-cancer MAbs with other immunotherapies

Chapter 4. Global Anticancer monoclonal antibodies Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Anticancer monoclonal antibodies Market, by Type

• 5.1. Market Snapshot
• 5.2. Global Anticancer monoclonal antibodies Market by Type, Performance - Potential Analysis
• 5.3. Global Anticancer monoclonal antibodies Market Estimates & Forecasts by Type 2020-2030 (USD Billion)
• 5.4. Anticancer monoclonal antibodies Market, Sub Segment Analysis
  • 5.4.1. Murine Antibodies
  • 5.4.2. Chimeric Antibodies
  • 5.4.3. Humanized Antibodies
  • 5.4.4. Other Types

Chapter 6. Global Anticancer monoclonal antibodies Market, by Application

• 6.1. Market Snapshot
• 6.2. Global Anticancer monoclonal antibodies Market by Application, Performance - Potential Analysis
• 6.3. Global Anticancer monoclonal antibodies Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
• 6.4. Anticancer monoclonal antibodies Market, Sub Segment Analysis
  • 6.4.1. Blood Cancer
  • 6.4.2. Breast Cancer
  • 6.4.3. Lung Cancer
  • 6.4.4. Melanoma
  • 6.4.5. Colorectal Cancer
  • 6.4.6. Liver Cancer
  • 6.4.7. Other Applications

Chapter 7. Global Anticancer monoclonal antibodies Market, by End User

• 7.1. Market Snapshot
• 7.2. Global Anticancer monoclonal antibodies Market by End User, Performance - Potential Analysis
• 7.3. Global Anticancer monoclonal antibodies Market Estimates & Forecasts by End User 2020-2030 (USD Billion)
• 7.4. Anticancer monoclonal antibodies Market, Sub Segment Analysis
  • 7.4.1. Hospitals
  • 7.4.2. Research Institutes
  • 7.4.3. Other End Users

Chapter 8. Global Anticancer monoclonal antibodies Market, Regional Analysis

• 8.1. Top Leading Countries
• 8.2. Top Emerging Countries
• 8.3. Anticancer monoclonal antibodies Market, Regional Market Snapshot
• 8.4. North America Anticancer monoclonal antibodies Market
  • 8.4.1. U.S. Anticancer monoclonal antibodies Market
    • 8.4.1.1. Type breakdown estimates & forecasts, 2020-2030
    • 8.4.1.2. Application breakdown estimates & forecasts, 2020-2030
    • 8.4.1.3. End User breakdown estimates & forecasts, 2020-2030
  • 8.4.2. Canada Anticancer monoclonal antibodies Market
• 8.5. Europe Anticancer monoclonal antibodies Market Snapshot
  • 8.5.1. U.K. Anticancer monoclonal antibodies Market
  • 8.5.2. Germany Anticancer monoclonal antibodies Market
  • 8.5.3. France Anticancer monoclonal antibodies Market
  • 8.5.4. Spain Anticancer monoclonal antibodies Market
  • 8.5.5. Italy Anticancer monoclonal antibodies Market
  • 8.5.6. Rest of Europe Anticancer monoclonal antibodies Market
• 8.6. Asia-Pacific Anticancer monoclonal antibodies Market Snapshot
  • 8.6.1. China Anticancer monoclonal antibodies Market
  • 8.6.2. India Anticancer monoclonal antibodies Market
  • 8.6.3. Japan Anticancer monoclonal antibodies Market
  • 8.6.4. Australia Anticancer monoclonal antibodies Market
  • 8.6.5. South Korea Anticancer monoclonal antibodies Market
  • 8.6.6. Rest of Asia Pacific Anticancer monoclonal antibodies Market
• 8.7. Latin America Anticancer monoclonal antibodies Market Snapshot
  • 8.7.1. Brazil Anticancer monoclonal antibodies Market
  • 8.7.2. Mexico Anticancer monoclonal antibodies Market
• 8.8. Middle East & Africa Anticancer monoclonal antibodies Market
  • 8.8.1. Saudi Arabia Anticancer monoclonal antibodies Market
  • 8.8.2. South Africa Anticancer monoclonal antibodies Market
  • 8.8.3. Rest of Middle East & Africa Anticancer monoclonal antibodies Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
  • 9.1.1. Company 1
  • 9.1.2. Company 2
  • 9.1.3. Company 3
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Amgen Inc.
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Recent Developments
  • 9.3.2. Bristol Myers Squibb Company
  • 9.3.3. Eli Lilly and Company
  • 9.3.4. F. Hoffmann-La Roche Ltd.
  • 9.3.5. Genmab AS
  • 9.3.6. Novartis AG
  • 9.3.7. Merck & Co., Inc.
  • 9.3.8. GlaxoSmithKline plc
  • 9.3.9. Johnson & Johnson Corp.
  • 9.3.10. AbbVie, Inc

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes
• 10.3. Research Assumption